Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| ProBioEtna | UNKNOWN |
Not provided
Not provided
Not provided
The aim of the present randomized double-blind placebo-controlled trial is to evaluate the efficacy of a probiotic formulation, containing the probiotic strain Lacticaseibacillus rhamnosus CA15 (DSM 33960), in the treatment of vaginal dysbiosis in terms of: (i) modulation of the microbiota (increase of lactobacilli and decrease of pathogens), (ii) reduction of clinical signs of inflammation, (iii) improvement of quality of life.
The aim of the present randomized double-blind placebo-controlled study is to evaluate the ability of the potential probiotic Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain, orally administrated, to balance the vaginal microbiota of women with vaginal dysbiosis. Two hundred women, with signs and symptoms of vaginal dysbiosis, are recruited and randomly allocated to receive oral capsules containing the L. rhamnosus CA15 (DSM 33960) strain or placebo once daily for 10 days. Clinical and microbiological parameters are evaluated in three scheduled appointments: at baseline (T0), 10 days after the start of the treatment (T1), and 30 days after the end of the treatment (T2). In addition, at baseline (T0) and 30 days after the end of the treatment (T2), the quality of life will be evaluated through a quality of life assessment questionnaire.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active | Active Comparator | 1 daily capsule of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain (10 billion of Colony Forming Units/capsule) for 10 days |
|
| Placebo | Placebo Comparator | 1 daily capsule of placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain | Dietary Supplement | Patients allocated to the probiotic arm will take the dietary supplement, containing 10 billion of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain, once a day for 10 consecutive days. |
| Measure | Description | Time Frame |
|---|---|---|
| Microbiota | Change in the composition of the vaginal microbiota (significant reduction of pathogens responsible for vaginal dysbiosis and concomitant increase in lactobacilli) | Baseline; end of the treatment (10 days); wash-out (30 days) |
| Symptomatology | Change of signs (leucorrhoea, vulvovaginal erythema/edema) and symptoms (vulvar discomfort, burning, itching) associated to vaginal dysbiosis. Clinical signs and symptoms will be evaluated through a severity score on a scale of 0 (absent or normal) to 3 (severe). | Baseline; end of the treatment (10 days); wash-out (30 days) |
| Sign | Absence of inflammation according to Amsel's criteria and Nugent score between 0 and 3 | Baseline; end of the treatment (10 days); wash-out (30 days) |
| Measure | Description | Time Frame |
|---|---|---|
| Well-being | Change in the quality of life, based on the Short Form-36 (SF-36) questionnaire. Values ranging from 0 to 100 indicate worst and better outcomes, respectively. | Baseline and wash-out (30 days) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Women under reproductive age
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marco Palumbo, Prof | University of Catania | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Catania | Catania | Italy | 95123 | Italy |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41471856 | Derived | Pino A, Vaccalluzzo A, Cianci S, Palumbo M, Caruso G, Caggia C, Randazzo CL. Oral Administration of the Probiotic Lacticaseibacillus rhamnosus CA15 in a Large Cohort of Women with Bacterial Vaginosis and Mixed Vaginitis: Clinical Evidence from a Randomized, Double-Blind, Placebo-Controlled Study. Microorganisms. 2025 Nov 21;13(12):2651. doi: 10.3390/microorganisms13122651. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
randomized double-blind placebo-control
Not provided
Not provided
Not provided
|
|
| placebo | Dietary Supplement | Patients allocated to placebo arm will take placebo capsules once a day for 10 consecutive days. |
|
| ID | Term |
|---|---|
| D016585 | Vaginosis, Bacterial |
| D002181 | Candidiasis, Vulvovaginal |
| D014552 | Urinary Tract Infections |
| ID | Term |
|---|---|
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D014627 | Vaginitis |
| D014623 | Vaginal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D002177 | Candidiasis |
| D009181 | Mycoses |
| D014848 | Vulvovaginitis |
| D014847 | Vulvitis |
| D014845 | Vulvar Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided